Safety and Efficacy Study of Lithium in Bipolar Disorder

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by JDS Pharmaceuticals.
Recruitment status was  Active, not recruiting
Information provided by:
JDS Pharmaceuticals Identifier:
First received: January 11, 2007
Last updated: August 13, 2007
Last verified: August 2007
The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.

Condition Intervention Phase
Bipolar Disorder
Drug: Lithium Carbonate Capsule
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder

Resource links provided by NLM:

Further study details as provided by JDS Pharmaceuticals:

Primary Outcome Measures:
  • change from baseline in YMRS score

Secondary Outcome Measures:
  • change from baseline in CGI-BP score
  • change from baseline in MADRS score

Estimated Enrollment: 206
Study Start Date: January 2007
Estimated Study Completion Date: December 2007

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Bipolar 1 Disorder;
  • Hospitalized or in the process of being hospitalized for a manic or mixed episode

Exclusion Criteria:

  • History of rapid cycling;
  • History of hypersensitivity or adverse reaction to lithium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00422331

United States, New York
JDS Pharmaceuticals
New York, New York, United States, 10174
Sponsors and Collaborators
JDS Pharmaceuticals
  More Information Identifier: NCT00422331     History of Changes
Other Study ID Numbers: JDS04004  Lithium TEAM-1 Study 
Study First Received: January 11, 2007
Last Updated: August 13, 2007
Health Authority: United States: Food and Drug Administration
India: Ministry of Health

Keywords provided by JDS Pharmaceuticals:
Bipolar I Disorder
Bipolar Disorder

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Pathologic Processes
Lithium Carbonate
Antidepressive Agents
Antimanic Agents
Central Nervous System Depressants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Tranquilizing Agents processed this record on May 26, 2016